. Author manuscript; available in PMC: 2009 Dec 15.

Published in final edited form as: Clin Cancer Res. 2008 Dec 15;14(24):8221–8227. doi: 10.1158/1078-0432.CCR-08-1841

Table 3.

Combined COX-2 and p53 status and patient survival in colon cancer

Combined COX-2/p53 status	Total N	Colon cancer-specific mortality			Overall mortality
		Deaths/person-years	Univeriate HR (95% CI)	Multivariate HR (95% CI)	Deaths/person-years	Univeriate HR (95% CI)	Multivariate HR (95% CI)
COX-2(-) p53(-)	91	16/844	1 (referent)	1 (referent)	37/844	1 (referent)	1 (referent)
COX-2(-) p53(+)	22	5/197	1.30 (0.48-3.55)	2.58 (0.89-7.48)	9/197	1.04 (0.50-2.16)	1.52 (0.71-3.24)
COX-2(+) p53(-)	313	85/2689	1.61 (0.95-2.75)	2.09 (1.19-3.65)	134/2689	1.13 (0.79-1.63)	1.35 (0.92-1.98)
COX-2(+) p53(+)	231	56/2089	1.41 (0.81-2.46)	2.20 (1.20-4.03)	102/2089	1.12 (0.77-1.63)	1.40 (0.93-2.11)
COX-2(+) total	544	141/4778	1.53 (0.91-2.56)	2.12 (1.23-3.65)	236/4778	1.12 (0.79-1.59)	1.37 (0.95-1.98)

The multivariate analysis model includes age at diagnosis, year of diagnosis, sex, tumor location, stage, grade, and statuses of KRAS, BRAF, microsatellite instability, and CpG island methylator phenotype.

p53 status was determined by immunohistochemistry.

CI, confidence interval; COX-2, cyclooxygenase-2 (PTGS2); HR, hazard ratio.